Efficacy

Beleodaq (Belinostat) for the Treatment of Lymphoma

Beleodaq (belinostat) is an anticancer medication specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a type of non-Hodgkin lymphoma that affects T-cells, and it is generally considered a rare and aggressive disease. The efficacy of Beleodaq was evaluated in a multicenter, single-arm clinical trial that involved patients with refractory or relapsed PTCL. Results from this study showed that belinostat produced a 25.8% overall response rate with a median duration of response of 8.4 months, indicating that it can be effective in inducing partial or complete responses in a subset of patients with this challenging condition.

The clinical trial data also demonstrated that some patients treated with Beleodaq experienced a progression-free survival benefit. However, it is important to note that the response to Beleodaq can vary significantly among individuals, and not all patients with PTCL will experience a favorable outcome. The safety and efficacy of Beleodaq for the treatment of other types of lymphoma have not been established, and its use in such cases would be considered off-label.

Jaypirca (Pirtobrutinib) for the Treatment of Lymphoma

Jaypirca (pirtobrutinib) is an investigational, orally administered, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor that is being studied for the treatment of B-cell malignancies, including various forms of lymphoma. While Jaypirca has not been formally approved by the FDA for any indication as of the knowledge cutoff date, clinical trials have been conducted to assess its efficacy in patients with B-cell malignancies who have failed other therapies, including those with BTK inhibitor resistance.

Preliminary results from ongoing clinical trials have shown promising activity of pirtobrutinib in patients with mantle cell lymphoma (MCL) and other B-cell lymphomas. In these studies, pirtobrutinib has demonstrated an ability to achieve objective responses in a significant proportion of patients, including those with prior BTK inhibitor exposure. As research continues, the efficacy and safety profile of Jaypirca will become clearer, and it may offer a new treatment option for patients with relapsed or refractory B-cell lymphomas.